Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say
I'm PortAI, I can summarize articles.
Hims & Hers Health Inc reported disappointing Q2 revenues, leading to a 4.5% drop in shares to $60.55. Analysts from BofA Securities and Needham expressed concerns over the company's near-term challenges, including stagnant core business growth and regulatory complexities from the ZAVA acquisition. BofA maintained an Underperform rating with a $28 price target, while Needham reiterated a Hold rating, noting revenue of $544.8 million fell short of expectations. The company faces hurdles in its GLP-1 and sexual health segments while planning expansions into hormonal health and Canada by 2026.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: Benzinga The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments